Takeda Ventures and Alexandria Venture Investments have taken part in a $70m series A round for Ensoma, with Takeda separately signing a strategic collaboration deal.
US-based genomic medicine developer Ensoma launched on Thursday with $70m in series A financing provided by investors including pharmaceutical firm Takeda and life sciences real estate investment trust Alexandria Real Estate Equities.
5AM Ventures led the round, which also included financial services group Fidelity’s F-Prime Capital unit, Viking Global Investors, Cormorant Asset Management, RIT Capital Partners and Symbiosis II.
Alexandria Real Estate Equities and Takeda invested through Alexandria Venture Investments and Takeda Ventures, respectively, with the latter supplying $10m.
Takeda…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
